QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CLDX

QT49Celldex Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
32.43
-0.50-1.52%
OverviewShort InterestFilings
CLDXQT49Celldex Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
32.43-1.52%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.01
Insider Own6.38%
Shs Outstand78.49M
Perf Week8.24%
Market Cap2.19BForward P/E-EPS next Y-4.38Insider Trans0.01%Shs Float-Perf Month7.56%
Enterprise Value2.16BPEG0.19EPS next Q-1.08Inst Own-Short Float-Perf Quarter7.99%
Income-283529831.00P/S2672.09EPS this Y-44.60%Inst Trans-Short Ratio-Perf Half Y21.55%
Sales820.00KP/B4.80EPS next Y-0.58%ROA-55.49%Short Interest-Perf YTD19.40%
Book/sh6.71P/C-EPS next 5Y-ROE-50.72%52W High35.79 -9.39%Perf Year61.67%
Cash/sh6.61P/FCF-EPS past 3/5Y-ROIC-67.01%52W Low19.52 66.14%Perf 3Y-
Dividend Est.-EV/EBITDA-7.70Sales past 3/5Y0.00% -22.16%Gross Margin-14287.93%Volatility2.66% 2.42%Perf 5Y-
Dividend TTM-EV/Sales2630.84EPS Y/Y TTM-73.88%Oper. Margin-37694.63%ATR (14)1.26Perf 10Y-
Dividend Ex-Date-Quick Ratio8.92Sales Y/Y TTM-14.29%Profit Margin-34596.22%RSI (14)57.76Recom2.00
Dividend Gr. 3/5Y-Current Ratio8.92EPS Q/Q-45.68%SMA205.84%Beta1.57Target Price49.00
Payout0.00%Debt/Eq0.00Sales Q/Q-100.00%SMA501.28%Rel Volume2.94Prev Close32.93
Employees186LT Debt/Eq0.00EarningsAug 06SMA20015.81%Avg Volume810.25KPrice32.43
IPO DateMay 15, 1986Option/ShortYes / YesEPS/Sales Surpr.-2.86% -100.00%Net Debt/EBITDA0.12Volume2,378,401Change-1.52%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedUBSBuy$45
May-13-26ReiteratedWells FargoOverweight$44 → $54
May-08-26ReiteratedBarclaysOverweight$45 → $48
Apr-20-26UpgradeBarclaysUnderweight → Overweight$24 → $45
Dec-17-25ReiteratedBarclaysUnderweight$21 → $24
Nov-11-25ReiteratedBarclaysUnderweight$25 → $21
Oct-13-25InitiatedBarclaysUnderweight$25
Mar-20-25InitiatedMorgan StanleyOverweight$46
Oct-29-24ReiteratedH.C. WainwrightBuy$80
Sep-25-24ReiteratedWells FargoEqual Weight$27 → $44
Latest News
Jun-15-26
Jun-15-2606:20AM
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price TargetBenzinga
03:02AM
Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF And TSLP Achieves Profound Mast Cell Depletion With Favorable Safety ProfileBenzinga
02:56AM
Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual MeetingBenzinga
Jun-10-26
Jun-10-2604:03PM
Celldex To Highlight Three Presentations From Barzolvolimab And CDX-622 Programs At EAACI Annual Congress 2026Benzinga
01:24PM
UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue627
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1530164
Gross Profit-1472-157
Selling, General and Administrative Excl. Other414439
Research and Development198245164
Other Operating Expense-1520-164
Operating Income-235-287-195
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-35-29-37
Net Income Before Taxes-200-259-158
Income Taxes000
Consolidated Net Income-200-259-158
Net Income From Continuing Operations-200-259-158
Net Income-200-259-158
EPS (Recurring)-3.01-3.90-2.45
EPS (Basic, Before Extraordinaries)-3.01-3.90-2.45
EPS (Diluted)-3.01-3.90-2.45
EBITDA-196-255-155
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio356.73909.86—
Gross Margin-2,450.00100.00-2,242.86
Operating Margin-3,916.67-14,350.00-2,785.71
Net Margin-3,333.33-12,950.00-2,257.14
Shares Outstanding666764
Market Capitalization2,1401,820—
Operating Lease Expense
———
Insider Trading Volume
$40.55$38.25$35.96$33.67$31.37● Close Price0.00M0.30M0.59M0.89M1.18MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Martin Samuel BatesSVP AND CFOJan 02 '26Option Exercise10.389,634100,00058,815Jan 06 12:00 AM
PEPIN RONALDSR. VP & CBODec 15 '25Option Exercise5.4738,666211,42820,097Dec 17 12:00 AM
Jimenez Freddy A.SVP & GENERAL COUNSELDec 04 '25Sale29.094,166121,21030,796Dec 08 12:00 AM
Wright Richard M.other: Former OfficerNov 13 '25Option Exercise14.0698,5961,385,82470,131Nov 17 12:00 AM
Wright Richard M.other: Former OfficerNov 13 '25Sale24.0049,2981,183,17720,833Nov 17 12:00 AM
Jimenez Freddy A.SVP & GENERAL COUNSELAug 13 '25Sale24.7777119,09534,962Aug 15 12:00 AM
Marucci Anthony SPRESIDENT & CEONov 11 '24Buy26.8211,500308,43040,284Nov 12 12:00 AM
Martin Samuel BatesSVP AND CFOJun 14 '24Option Exercise10.1640,338409,98063,632Jun 18 12:00 AM
Martin Samuel BatesSVP AND CFOJun 14 '24Sale35.4217,172608,31528,125Jun 18 12:00 AM
Crowley ElizabethSR. VP & CPDOJun 14 '24Option Exercise10.3860,000622,80046,500Jun 18 12:00 AM
Crowley ElizabethSR. VP & CPDOJun 14 '24Sale34.8730,0001,045,9629,074Jun 18 12:00 AM
Young Diane C.SVP, CHIEF MEDICAL OFFICERJun 11 '24Option Exercise2.7130,00081,30017,115Jun 13 12:00 AM
Crowley ElizabethSR. VP & CPDOJun 07 '24Option Exercise9.7030,000290,94876,500Jun 11 12:00 AM
Crowley ElizabethSR. VP & CPDOJun 07 '24Sale35.0615,000525,8739,074Jun 11 12:00 AM
Young Diane C.SVP, CHIEF MEDICAL OFFICERJun 07 '24Sale35.2645,0001,586,8442,115Jun 11 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR